Suppression of myasthenia gravis by antigen-specific mucosal tolerance and modulation of cytokines and costimulatory factors

Annals of the New York Academy of Sciences

Volumn 998, Issue , 2003, Pages 533-536

  Souroujon, Miriam C ^a,b   Maiti, Prasanta K ^a   Feferman, Tali ^a   Im, Sin Hyeog ^a,c   Raveh, Lily ^d   Fuchs, Sara ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b OPEN UNIVERSITY OF ISRAEL   (Israel)

^c Gwangju Institute of Science and Technology (GIST)   (South Korea)

^d ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

Costimulatory factors; Cytokines; Mucosal tolerance; Suppression of ongoing EAMG; Syngeneic recombinant fragments; Synthetic peptides

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CHOLINERGIC RECEPTOR; CYTOKINE; INTERLEUKIN 18; RECEPTOR SUBUNIT; RECOMBINANT RECEPTOR; SYNTHETIC PEPTIDE;

ALPHA CHAIN; ANTIGEN SPECIFICITY; CONFERENCE PAPER; DISEASE COURSE; HUMAN; IMMUNOPATHOGENESIS; MYASTHENIA GRAVIS; NONHUMAN; PROTEIN DOMAIN;

ANIMALIA;

EID: 0141838984     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1254.069     Document Type: Conference Paper

References (10)

1. BARCHAN, D., M.C. SOUROUJON, S-H. IM et al. 1999. Antigen-specific modulation of experimental myasthenia gravis: nasal tolerization with recombinant fragments of the human acetylcholine receptor α-subunit. Proc. Natl. Acad. Sci. USA 96: 8086-8091.
2. IM, S-H., D. BARCHAN, S. FUCHS & M.C. SOUROUJON. 1999. Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment. J. Clin. Invest. 104: 1723-1728.
3. IM, S-H., D. BARCHAN, S. FUCHS & M.C. SOUROUJON. 2000. Mechanism of nasal tolerance induced by a recombinant fragment of acetylcholine receptor for treatment of experimental myasthenia gravis. J. Neuroimmunol. 111: 161-168.
4. KUCHROO, V.K., M.P. DAS, J.A. BROWN et al. 1995. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80: 707-718.
5. THOMPSON, C.B. 1995. Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation. Cell 81: 979-982.
6. IM, S-H., D. BARCHAN, M.C. SOUROUJON & S. FUCHS. 2000. Role of tolerogen conformation in induction of oral tolerance in experimental autoimmune myasthenia gravis. J. Immunol. 165: 3599-3605.
7. SHI, F.D., H.B. WANG, H. LI et al. 2000. Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat. Immunol. 1: 245-251.
8. SHI, F.D., B. HE, H. LI et al. 1998. Differential requirements for CD28 and CD40 ligand in the induction of experimental autoimmune myasthenia gravis. Eur. J. Immunol. 28: 3587-3593.
9. IM, S-H., D. BARCHAN, P.K. MAITI et al. 2001. Blockade of CD40 ligand suppresses chronic experimental myasthenia by downregulation of Th1 differentiation and upregulation of CTLA-4. J. Immunol. 166: 6893-6898.
10. IM, S-H., D. BARCHAN, P.K. MAITI et al. 2001. Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18. FASEB J. 15: 2140-2148.